1. Verrijken, A, Francque, S, Van Gaal, L. The metabolic syndrome and the liver. Acta Gastroenterol Belg 2008; 71: 48–59.
Google Scholar | Medline2. Van Gaal, LF, Mertens, IL, De Block, CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875–880.
Google Scholar | Crossref | Medline3. Arab, JP, Arrese, M, Trauner, M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol 2018; 13: 321–350.
Google Scholar | Crossref | Medline4. Younossi, Z, Anstee, QM, Marietti, M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11–20.
Google Scholar | Crossref | Medline5. Kanwal, F, Kramer, JR, Duan, Z, et al. Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans. Clin Gastroenterol Hepatol 2016; 14: 301–308.e2.
Google Scholar | Crossref | Medline6. EASL-EASD-EASO . EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388–1402.
Google Scholar | Crossref | Medline7. Chalasani, N, Younossi, Z, Lavine, JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of liver diseases. Hepatology 2018; 67: 328–357.
Google Scholar | Crossref | Medline8. Orci, LA, Sanduzzi-Zamparelli, M, Caballol, B, et al. Incidence of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin Gastroenterol Hepatol 2021. Epub ahead of print 28 May 2021.
Google Scholar | Crossref | Medline9. Younossi, ZM, Koenig, AB, Abdelatif, D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
Google Scholar | Crossref | Medline10. Younossi, ZM, Golabi, P, de Avila, L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019; 71: 793–801.
Google Scholar | Crossref | Medline11. Orman, ES, Mayorga, ME, Wheeler, SB, et al. Declining liver graft quality threatens the future of liver transplantation in the United States. Liver Transplant 2015; 21: 1040–1050.
Google Scholar | Crossref | Medline12. Bian, H, Zhu, X, Xia, M, et al. Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract 2020; 26: 444–453.
Google Scholar | Crossref | Medline13. Alexander, M, Loomis, AK, Van der Lei, J, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ 2019; 367: l5367.
Google Scholar | Crossref | Medline14. Kasper, P, Martin, A, Lang, S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021; 110: 921.
Google Scholar | Crossref | Medline15. Mantovani, A, Byrne, CD, Bonora, E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 2018; 41: 372–382.
Google Scholar | Crossref | Medline16. Gastaldelli, A, Cusi, K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep 2019; 1: 312–328.
Google Scholar | Crossref | Medline17. Hammarstedt, A, Gogg, S, Hedjazifar, S, et al. Impaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity. Physiol Rev 2018; 98: 1911–1941.
Google Scholar | Crossref | Medline18. Petta, S, Gastaldelli, A, Rebelos, E, et al. Pathophysiology of non alcoholic fatty liver disease. Int J Mol Sci 2016; 17: 2082.
Google Scholar | Crossref | Medline19. Shulman, GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014; 371: 1131–1141.
Google Scholar | Crossref | Medline20. Krssak, M, Falk Petersen, K, Dresner, A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1 H NMR spectroscopy study. Diabetologia 1999; 42: 113–116.
Google Scholar | Crossref | Medline21. Ter Horst, KW, Serlie, MJ. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients 2017; 9(9): 981.
Google Scholar22. Buzzetti, E, Pinzani, M, Tsochatzis, EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038–1048.
Google Scholar | Crossref | Medline23. Rada, P, González-Rodríguez García-Monzón, C, et al. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis 2020; 11: 802.
Google Scholar | Crossref | Medline24. Piazzolla, VA, Mangia, A. Noninvasive diagnosis of NAFLD and NASH. Cells 2020; 9: 1005.
Google Scholar | Crossref | Medline25. Dyson, JK, Anstee, QM, McPherson, S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Front Gastroenterol 2014; 5: 211–218.
Google Scholar | Crossref | Medline26. Kahl, S, Straßburger, K, Nowotny, B, et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One 2014; 9: e94059.
Google Scholar | Crossref | Medline27. Pu, K, Wang, Y, Bai, S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol 2019; 19: 51.
Google Scholar | Crossref | Medline28. Loomba, R, Neuschwander-Tetri, BA, Sanyal, A, et al. Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH. Hepatology 2020; 72: 1219–1229.
Google Scholar | Crossref | Medline29. Van Gaal, LF, Wauters, MA, De Leeuw, IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21: S5–S9.
Google Scholar | Medline30. Li, G, Zhang, P, Wang, J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing diabetes prevention study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014; 2: 474–480.
Google Scholar | Crossref | Medline31. Gong, Q, Zhang, P, Wang, J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol 2019; 7: 452–461.
Google Scholar | Crossref | Medline32. Petersen, KF, Dufour, S, Befroy, D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603–608.
Google Scholar | Crossref | Medline33. Holmer, M, Lindqvist, C, Petersson, S, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet: a randomised controlled trial. JHEP Rep 2021; 3: 100256.
Google Scholar | Crossref | Medline34. De Souza, RJ, Bray, GA, Carey, VJ, et al. Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. Am J Clin Nutr 2012; 95: 614–625.
Google Scholar | Crossref | Medline35. Van Gaal, L, Dirinck, E. Pharmacological approaches in the treatment and maintenance of weight loss. Diabetes Care 2016; 39: S260–S267.
Google Scholar | Crossref | Medline36. Lazo, M, Solga, SF, Horska, A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010; 33: 2156–2163.
Google Scholar | Crossref | Medline37. Promrat, K, Kleiner, DE, Niemeier, HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121–129.
Google Scholar | Crossref | Medline38. Francque, S, Vonghia, L. The future of diagnosing NASH – could a simple blood test be the key? Expert Rev Gastroenterol Hepatol 2017; 11: 995–997.
Google Scholar | Crossref | Medline39. Lim, EL, Hollingsworth, KG, Aribisala, BS, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011; 54: 2506–2514.
Google Scholar | Crossref | Medline40. Vilar-Gomez, E, Martinez-Perez, Y, Calzadilla-Bertot, L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149: 367–378.e5. quiz e14-5.
Google Scholar | Crossref41. Lean, ME, Leslie, WS, Barnes, AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541–551.
Google Scholar | Crossref | Medline42. Lean, MEJ, Leslie, WS, Barnes, AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2019; 7: 344–355.
Google Scholar | Crossref | Medline43. Al-Mrabeh, A, Zhyzhneuskaya, SV, Peters, C, et al. Hepatic lipoprotein export and remission of human type 2 diabetes after weight loss. Cell Metab 2020; 31: 233–249.e4.
Google Scholar | Crossref | Medline44. Taylor, R, Al-Mrabeh, A, Sattar, N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol 2019; 7: 726–736.
Google Scholar | Crossref | Medline45. Saeed, N, Nadeau, B, Shannon, C, et al. Evaluation of dietary approaches for the treatment of non-alcoholic fatty liver disease: a systematic review. Nutrients 2019; 11: 3064.
Google Scholar | Crossref46. Schwenger, KJ, Allard, JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1712–1723.
Google Scholar | Crossref | Medline47. Romero-Gómez, M, Zelber-Sagi, S, Trenell, M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017; 67: 829–846.
Google Scholar | Crossref | Medline48. Golabi, P, Locklear, CT, Austin, P, et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: systematic review. World J Gastroenterol 2016; 22: 6318.
Google Scholar | Crossref | Medline49. Orci, LA, Gariani, K, Oldani, G, et al. Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression. Clin Gastroenterol Hepatol 2016; 14: 1398–1411.
Google Scholar | Crossref | Medline50. Houghton, D, Thoma, C, Hallsworth, K, et al. Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial. Clin Gastroenterol Hepatol 2017; 15: 96–102.e3.
Google Scholar | Crossref | Medline51. Linden, MA, Sheldon, RD, Meers, GM, et al. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis. J Physiol 2016; 594: 5271–5284.